Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been given an average rating of “Hold” by the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $28.75.

LXRX has been the topic of a number of analyst reports. BidaskClub cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Wedbush reiterated an “ourperform” rating and issued a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th.

TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of “Hold” by Analysts” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/09/05/lexicon-pharmaceuticals-inc-lxrx-given-average-rating-of-hold-by-analysts.html.

Several hedge funds have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $182,000. First Mercantile Trust Co. boosted its stake in shares of Lexicon Pharmaceuticals by 11.2% during the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 1,227 shares in the last quarter. Cim Investment Mangement Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $262,000. Pacad Investment Ltd. bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $265,000. Finally, Legal & General Group Plc boosted its stake in shares of Lexicon Pharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 465 shares in the last quarter.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 14.48 on Tuesday. Lexicon Pharmaceuticals has a 12-month low of $13.41 and a 12-month high of $19.62. The company has a 50-day moving average price of $15.28 and a 200-day moving average price of $15.42. The firm’s market capitalization is $1.53 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $12 million for the quarter, compared to analysts’ expectations of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm’s revenue was down 40.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.37) EPS. Equities analysts predict that Lexicon Pharmaceuticals will post ($1.45) EPS for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.